Alogliptin (nesina) for adults with type-2 diabetes.

Standards of Medical Care in Diabetes—2013

Diabetes Care · 2012 · 4.4K citations · Full text

Medicine, Internal Medicine, Clinical Epidemiology +13

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

S. E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetologia · 2012 · 3.9K citations · Full text

Medicine, Endocrinology, Internal Medicine +13

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

William B. White, Christopher P. Cannon, Simon Heller et al. · New England Journal of Medicine · 2013 · 2.5K citations · Full text

Medicine, Cardiology, Internal Medicine +14

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control

Ralph A. DeFronzo, P. Fleck, Craig Wilson et al. · Diabetes Care · 2008 · 224 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

Michael A. Nauck, Graham C. Ellis, P. Fleck et al. · International Journal of Clinical Practice · 2008 · 205 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17